Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Posts No Revenues in 2009

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion last week reported it had no revenues in 2009, compared to $124,000 in revenues in 2008. Meanwhile, its net loss for the year rose 20 percent to more than $22 million in 2009, compared to $18.3 million the year before.

The figures were reported as part of the company's annual earnings documents filed with the US Securities and Exchange Commission. The Fremont, Calif.- based proteomics diagnostics firm spent nine months of 2009 in Chapter 11 bankruptcy protection as it awaited a decision by the US Food and Drug Administration on its 510(k) submission for its triage ovarian cancer test, called OVA1.

The FDA cleared the test in September, and earlier this year Vermillion emerged from Chapter 11.

Vermillion and partner Quest Diagnostics began marketing the test in March.

For the year ended Dec. 31, 2009, Vermillion's R&D spending slid 56 percent to slightly more than $2.3 million, compared to nearly $5.3 million in 2008. Its SG&A costs dropped 67 percent to $3 million in 2009 from $9.3 million in FY 2008.

As of Dec. 31, Vermillion said it had $3.4 million in cash and cash equivalents.

In January, the company received about $43.1 million as part of a private placement with a group of investors, and late last month, it said its cash and cash equivalents as of March 31 were approximately $37.7 million.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.